MS
CYT

Maven Securities’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Maven Securities’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,870
Closed -$217K – 1329
2021
Q2 		$217K Buy
+10,870
New +$204K 0.01% 918

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maven Securities's CYT Position: Q3 2021 in Review

Maven Securities sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q3 2021, closing a stake of 10,870 shares — an estimated $217K sold.

Maven Securities first reported a position in CYT in Q2 2021 and held it in 1 quarter. The position peaked at $217K in Q2 2021. 38 funds tracked by Wall St. Rank hold CYT as of Q3 2021.

  • Maven Securities reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 10,870 Cyteir Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $217K.
  • Maven Securities first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Maven Securities's Cyteir Therapeutics, Inc. Common Stock position peaked at $217K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.